Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia - PubMed
4 hours ago
- #Vaccine Efficacy
- #Immunogenicity
- #COVID-19
- The study compares immunogenicity and efficacy over 12 months following a fourth dose of bivalent mRNA (Moderna) or protein-based (Novavax) COVID-19 vaccines.
- Participants were randomized to receive either Moderna (n=177), Novavax (n=176), or no fourth dose (control, n=143).
- Moderna showed higher IgG levels against the Ancestral strain and Omicron variants (BA.1, BA.4/5, JN.1) at 6 and 12 months compared to Novavax.
- No differences in T cell immunity (IGRA) were observed between Moderna and Novavax groups.
- Both vaccines provided higher IgG GMCs against the Ancestral strain and Omicron variants compared to the control group at both timepoints.
- Infection rates over 12 months were lower in both vaccine groups (Moderna: 43.0%, Novavax: 47.0%) compared to the control group (68.1%).
- The bivalent Moderna vaccine induced higher immune responses than Novavax, but both offered comparable protection against Omicron variants over 12 months.